Poxel’s Phase II Data Add AMP Kinase Activation To NASH Possibilities

 
• By Joseph Haas

Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.

businessman chooses the path strategy
Add AMPK activation to the mechanisms of action now in mid-stage NASH development

More from Clinical Trials

More from R&D